Z-1566-2014Class I

ABACUS TPN Calculation Software, Product Codes: 8300-0045 ABACUS CE (Calculator Edition), 8300-0046 ABACUS SE...

Name: Z-1566-2014 ABACUS TPN Calculation Software, Product Codes: 8300-0045 ABACUS CE (Calculator Edition), 8300-0046 ABACUS SE...
Creator: Baxter Corporation Englewood
Published: 2014-04-02
License: https://open.fda.gov/license/

Baxter Corporation Englewood / initiated 2014-04-02 / Terminated / root cause: software

FDA source

Baxter Corporation Englewood began a recall of ABACUS TPN Calculation Software, Product Codes: 8300-0045 ABACUS CE (Calculator Edition), 8300-0046 ABACUS SE (Single-Workstation Edition), 8300-0047 ABACUS ME... on 2014-04-02. FDA classified it as Class I and gives the reason as "1. ABACUS v3.1 may calculate quantities of electrolytes that are double the expected values during the creation of TPN orders. 2. ABACUS v3.1 may automatically add additional sterile water to a formula equal to the...". As of 2026-09-10, the recall status on record is Terminated, and MDM tags the root cause as software.

Recall record

Recall number: Z-1566-2014
Classification: Class I
Status: Terminated
Initiated: 2014-04-02
Posted: 2014-05-12
Terminated: 2016-01-20
Recalling firm: Baxter Corporation Englewood
Product: ABACUS TPN Calculation Software, Product Codes: 8300-0045 ABACUS CE (Calculator Edition), 8300-0046 ABACUS SE (Single-Workstation Edition), 8300-0047 ABACUS ME (Multi-Workstation Edition), 8300-0156 ABACUS 3.0 CE, 8300-0157 ABACUS 3.0 SE, 8300-0158 ABACUS 3.0 ME, 8300-0166 ABACUS 3.1 DE, 8300-0167 ABACUS 3.1 CE, 8300-0168 ABACUS 3.1 SE, 8300-0169 ABACUS 3.1 ME. ABACUS is a Windows - based order entry TPN software application for comprehensive calculations and label printing. The primary use of Abacus is for Total Parenteral Nutrition (TPN) order calculations.
Product code: NEP System/Device, Pharmacy Compounding
Reason for recall: 1. ABACUS v3.1 may calculate quantities of electrolytes that are double the expected values during the creation of TPN orders. 2. ABACUS v3.1 may automatically add additional sterile water to a formula equal to the volume of a premix resulting in an over dilution. 3. All software versions of ABACUS software display the calcium phosphate curve points for Premasol incorrectly. 4. All software v
Root cause tag: software
FDA root cause: Software design
Action: Baxter sent an Urgent Device Correction letter dated April 21, 2014, to all affected customers. The letter identified the product, the problem, and the action to be taken by the customer. . 1. Follow safe compounding practice, which includes 1) using of the Summary button to verify the order against the calculated amounts prior to completing the order, 2) verifying that the ordered ingredients and quantities displayed in the software and printed on the Bag label and the Solution Formula label match the PN prescription prior to preparation, and 2) using a filter for administration of a PN bag. Use of the ABACUS Software must comply with your facility's policies, procedures, and training, including verification that all information entered into the ABACUS Software is accurate and clinically appropriate. 2. To determine if any of these Issues are present in your current ABACUS configuration, please note the following immediate actions should be taken: "Double Salts: Baxter contacted all facilities installed by Baxter with ABACUS v3.1 to correct the Double Salts Issue via telephone between April 4, and April 16, 2014.To avoid the Double Salts Issue, a pharmacy installed with ABACUS v3.1 should 1) ensure the "Include non-electrolyte ion contributions in balance" checkbox is checked for all salt-based templates, and 2) compare the ordered amount of salts to the delivered amount on the Ions tab in ABACUS. "Sterile Water Added to TPN with Pre-Mix: Customer should ensure that all premix not intended for use on the compounder are marked as "Pre-Mix PN Solution" type in the Formulary. Customer should then check the template, under the "Infusion" tab, to ensure the "Infusion Mode" is set to "Pre-Mix (Cyclic)". "Premasol CaP04 Curve Data Points: Review Attachment 1 for information relevant to the use of calcium phosphate curves for Premasol 3% Dex 25
Quantity in commerce: 2034
Distribution: Worldwide Distribution - USA nationwide, Canada, Colombia, Dominican Republic, Panama, Austria, Bosnia Herzegovina, Bulgaria, Bahrain, Estonia, France, Germany, Georgia, Hungary, Ireland, Israel, Jordan, Kuwait, Latvia, Morocco, Oman, Qatar, Saudi Arabia, Slovenia, Slovakia, South Africa, Switzerland, United Arab Emirates, United Kingdom, Hong Kong, and Taiwan.
Product codes and lots: Product Code 8300-0045, 8300-0046, 8300-0047, 8300-0156, 8300-0157, 8300-0158, 8300-0166, 8300-0167, 8300-0168, 8300-0169

Enforcement reports

One row per recalled product line

FDA enforcement reports joined to recall event Z-1566-2014
Recall number	Class	Status	Voluntary or mandated	Report date	Classified
Z-1566-2014	Class I	Terminated	Voluntary: Firm initiated	2014-05-21	2014-05-12

Product code NEP

The FDA recall record names no cleared device, and no clearance has been matched to it.

MDM coverage of this record lists here, newest first.

About this record

Sourced from the FDA device recall database and the FDA enforcement reports, both ingested from openFDA. The recall record supplies the product, the reason and the product code; the enforcement report supplies the classification. The two datasets are exported by FDA on different days, and the date above is the older of the two, so nothing on this page is newer than it says.

MDM adds the root cause tag, derived from FDA’s own root cause text, and the cross-links to the product code, the clearances named on the record and MDM coverage. Where a recall has not been joined to an enforcement report, no classification is shown.

Data as of 2026-09-30, the FDA export date for this dataset. Page last changed 2026-09-05. View this recall on fda.gov (opens on fda.gov)